Company intelligence / Profile preview

Legends

Somerset, New Jersey, USA

Ownership: Private
Employees: ~1100
Development stage: Other

Overview

Legend Biotech received FDA approval for ciltacabtagene autoleucel (CARVYKTI®) in relapsed/refractory multiple myeloma in 2022; latest 5-year survival data presented at ASCO 2025 are described as groundbreaking. CARVYKTI demonstrates unprecedented efficacy in heavily pre-treated patients and is marketed primarily in partnership with Janssen Biotech. Expanding pipeline includes novel CAR-T assets in solid tumors (DLL3).

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCAR-NK cell therapyCAR-γδ T cell therapyNanobody therapyGene therapyBiologicAntibody
Industry: Biotech

Partnerships

Janssen Biotech (Johnson & Johnson)Novartis

Beyond the preview

Go deeper on Legends.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Legends.

Explore the full profile